Innovative biotechnologies: bacteriophages against infections

A new facility

Architecte : AIA LIFE DESIGNERS - Photos ©G.Satre

As part of the forthcoming installation of its bacteriophage GMP production site, Pherecydes Pharma opens a second facility in Nantes.

The facility will be located 22 boulevard Benoni Goullin, in the Nantes Biotech business incubator on the Isle of Nantes.

Work started in early September 2018 is scheduled to be completed by the end of March 2019.


PhagoPROD, a pioneer production site in Europe

Architecte : AIA LIFE DESIGNERS - Photo ©G.Satre

Throught its PhagoPROD project, Pherecydes Pharma was chosen to illustrate the "Health" topic of the "InvestEU" European Communication campaign, as part of its support to innovative companies, via the "SME Instrument" H2020.

This project is dedicated to manufacture bacteriophages in Europe according to standards of pharmaceutical Good Manufacturing Pratices (GNP).


Last ressort treatment against Staphylococcus aureus

Local administration of a phage anti-staphylococcal mixture associated to antibiotics prevented the removal of a hip prosthesis, which would have led to a loss of mobility of the patient's leg.

With 20 months of relapse-free recurrence today, this treatment of last resort is considered a success.


Magali Vidal-Engaurran, Senior Pharmacist

Magali Vidal-Engaurran joins the Pherecydes Pharma Management Board to assume the position of Pharmacist – Qualified Person. With more than 15 years of experience, she will be responsible for setting up Good Manufacturing Practices (GMPs) within the production unit in Nantes and obtaining the status of a pharmaceutical manufacturer.


Salvage therapy

Four bacteriophages provided by Pherecydes Pharma to the Hospices Civils de Lyon have eliminated a bacterial infection induced by a Pseudomonas aeruginosa strain toto-resistant to antibiotics.

The description of this first case of compassionate treatment performed by Professor Tristan Ferry's team, in 2017, was published in the Journal of Antimicrobial in October 2018.


PhagoBurn, promising results


The results of PhagoBurn's first randomized, double-blind, multi-center clinical trial about phage therapy have just been published in The Lancet Infectious Disease.

This study demonstrates for the first time in an objective manner the action of phages to treat burns infected with Pseudomonas aeruginosa in severely burnt patients hospitalized in intensive care units.


In less than 10 years, Pherecydes Pharma has established itself as the champion of phage therapy. Following the development of the first pharmaceutical manufacturing process for bacteriophage, Pherecydes Pharma is the first company to have obtained authorizations for conducting a clinical trial to directly test its phages on hospitalized patients.

Jérôme Gabard, Chief Operating Officer at Pherecydes Pharma

Guy-Charles Fanneau de La Horie

Antibiotic resistance is a major health challenge in the years to come: 10 million people may die in 2050. New approaches are needed; Phage therapy represents the most promising hope. Pherecydes Pharma makes every effort to provide physicians and patients with effective treatments for the most serious bacterial infections.

Guy-Charles Fanneau de La Horie, Chief Executive Officer at Pherecydes Pharma


You can view all the information here

Pherecydes-Pharma is member of

Medicen Adebiotech Leem Beam Alliance Biocitech France Biotech